<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><description>BiG，Biologics Innovation Group是由致力于从事生物医药领域研究、开发、应用、临床、投资等工作的独立个人，自愿组织的一个专业/非盈利性机构。正式成立于2014年，迄今会员490余人，相继举办20余场行业峰会。</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 01 Feb 2021 20:33:08 +0800</pubDate><image><url>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</url><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>AML治疗新策略，CD33双抗！</title><link>https://mp.weixin.qq.com/s/y4j0jgtuVILD5d6678cKjA</link><description></description><content:encoded><![CDATA[AML治疗新策略，CD33双抗！]]></content:encoded><pubDate>Mon, 01 Feb 2021 17:22:53 +0800</pubDate></item><item><title>新江湖｜益莱生物加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/ea3sqP9h4bf6PVyWQUSJbA</link><description></description><content:encoded><![CDATA[新江湖｜益莱生物加入BiG会员机构！]]></content:encoded><pubDate>Mon, 01 Feb 2021 17:22:53 +0800</pubDate></item><item><title>王晓东｜从NIBS走出的维泰瑞隆，做药的逻辑是什么？</title><link>https://mp.weixin.qq.com/s/v6A4IXS_2LCUwZf2J-rsag</link><description></description><content:encoded><![CDATA[王晓东｜从NIBS走出的维泰瑞隆，做药的逻辑是什么？]]></content:encoded><pubDate>Thu, 28 Jan 2021 18:02:49 +0800</pubDate></item><item><title>多抗潮头，创药蓝海｜第七届BiG年会来了！</title><link>https://mp.weixin.qq.com/s/qgqCame67NjttxHhUkbJzw</link><description></description><content:encoded><![CDATA[多抗潮头，创药蓝海｜第七届BiG年会来了！]]></content:encoded><pubDate>Thu, 28 Jan 2021 17:56:01 +0800</pubDate></item><item><title>进击吧，细胞因子！IL-2和IL-15的单药及Combo</title><link>https://mp.weixin.qq.com/s/sffBLdxE1wbndXp9BQqTig</link><description></description><content:encoded><![CDATA[进击吧，细胞因子！IL-2和IL-15的单药及Combo]]></content:encoded><pubDate>Wed, 27 Jan 2021 17:01:53 +0800</pubDate></item><item><title>新江湖｜ 春天医药加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/1sJIoQZC3UosU99bLFDS0Q</link><description></description><content:encoded><![CDATA[新江湖｜ 春天医药加入BiG会员机构！]]></content:encoded><pubDate>Wed, 27 Jan 2021 17:01:53 +0800</pubDate></item><item><title>Nature Cancer｜新型ADC：Bolt Bio公司ISACs</title><link>https://mp.weixin.qq.com/s/GPjMctX-31whm08tADGvWw</link><description></description><content:encoded><![CDATA[Nature Cancer｜新型ADC：Bolt Bio公司ISACs]]></content:encoded><pubDate>Mon, 25 Jan 2021 17:01:35 +0800</pubDate></item><item><title>荐 | 保护药品研发成果，这2项专利制度你必须知道！</title><link>https://mp.weixin.qq.com/s/lxTPJxhmi2pTycA7vFqS3Q</link><description></description><content:encoded><![CDATA[荐 | 保护药品研发成果，这2项专利制度你必须知道！]]></content:encoded><pubDate>Mon, 25 Jan 2021 17:01:35 +0800</pubDate></item><item><title>盘点｜肿瘤干细胞药物开发的四条通路及主要靶点！</title><link>https://mp.weixin.qq.com/s/e_cvInoUSPsnN14ZDnskvw</link><description></description><content:encoded><![CDATA[盘点｜肿瘤干细胞药物开发的四条通路及主要靶点！]]></content:encoded><pubDate>Fri, 22 Jan 2021 15:48:53 +0800</pubDate></item><item><title>新江湖｜徐琦、刘佳凝、朱枫、郎帼娜、张妍加入BiG！</title><link>https://mp.weixin.qq.com/s/409dsez7olZOYA6cYjrWxQ</link><description></description><content:encoded><![CDATA[新江湖｜徐琦、刘佳凝、朱枫、郎帼娜、张妍加入BiG！]]></content:encoded><pubDate>Fri, 22 Jan 2021 15:48:53 +0800</pubDate></item><item><title>又一重磅Deal, 科望医药1.17亿美元引入VEGF/DLL4双抗！</title><link>https://mp.weixin.qq.com/s/8oFUIgWiSOFLQfIT4OQ-Jg</link><description></description><content:encoded><![CDATA[又一重磅Deal, 科望医药1.17亿美元引入VEGF/DLL4双抗！]]></content:encoded><pubDate>Thu, 21 Jan 2021 13:00:35 +0800</pubDate></item><item><title>五位大咖谈IO｜单抗/ADC赛道，新靶点如何困境突围？</title><link>https://mp.weixin.qq.com/s/g1qSsbCfB4nXK9KEUGdRMA</link><description></description><content:encoded><![CDATA[五位大咖谈IO｜单抗/ADC赛道，新靶点如何困境突围？]]></content:encoded><pubDate>Tue, 19 Jan 2021 17:00:05 +0800</pubDate></item><item><title>新江湖｜自贸壹号加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/nT6b1qb23k0zea_VOA6jBg</link><description></description><content:encoded><![CDATA[新江湖｜自贸壹号加入BiG会员机构！]]></content:encoded><pubDate>Tue, 19 Jan 2021 17:00:05 +0800</pubDate></item><item><title>阿斯利康PD-1/CTLA-4双抗，增强对PD-1+活化T细胞CTLA-4的阻断作用</title><link>https://mp.weixin.qq.com/s/BogmE5ys86BAHGRJspYqyg</link><description></description><content:encoded><![CDATA[阿斯利康PD-1/CTLA-4双抗，增强对PD-1+活化T细胞CTLA-4的阻断作用]]></content:encoded><pubDate>Fri, 15 Jan 2021 17:00:59 +0800</pubDate></item><item><title>五位大咖谈CAR-T｜成本及定价，降VS不降，谁说了算？</title><link>https://mp.weixin.qq.com/s/GHuZBr3dwkN7nW3HAw6a7g</link><description></description><content:encoded><![CDATA[五位大咖谈CAR-T｜成本及定价，降VS不降，谁说了算？]]></content:encoded><pubDate>Thu, 14 Jan 2021 07:52:29 +0800</pubDate></item><item><title>邀 | Biofuture 2021 下一代抗体药技术创新大会 &amp; 细胞与基因治疗创新大会</title><link>https://mp.weixin.qq.com/s/4eQX39EgvSm1umnXuCrBoA</link><description></description><content:encoded><![CDATA[邀 | Biofuture 2021 下一代抗体药技术创新大会 & 细胞与基因治疗创新大会]]></content:encoded><pubDate>Thu, 14 Jan 2021 07:52:29 +0800</pubDate></item></channel></rss>